Write a Comment
6 Comments
Sorry, can't get on board with the animal testing.
It's not clear to me from this article whether the vaccine candidate prevents infection or modifies the progress of infection in an animal that is already SIV infected. If the monkeys were vaccinated before being infected, then what's the applicability for those already infected who are then given the vaccine? Can you do a followup article on this? Thanks. PS the photo on your website is that of a chimpanzee, not a monkey. But I'm just sayin'
Eddie Hi , I am in Houston area at the moment. I say wow, this is great news and I will sign up for the treatment now for it sounds just as safe as FDA approved ARVs. NIH needs to step up and USA leaders to set a side funding for a scale up to help this science move foward as an Emergency Effort to Cure AIDS. These conference on open science should be followed up with support and action to rethink USA research funding. Think it could save Trillions of dollars and Millions of lives.
McGarrity did not report on plans for testing in HIV-positive people, but it is likely that the company will continue to refine and increase the potency of its vaccine candidates before moving into human testing. To me the title of this article was more exciting than its context. I read nothing but vague news. Tell me, Do you have the Bomb or not? just like they would say in the Manhattan project.
Congratulations VIRxSYS!
David Evans, Editor, AIDSmeds
Dear poznrgman - You are right that in this case the SIV vaccine was used pre-infection to determine its impact on viral load and progression in the monkeys- but the human candidate is intended to be used therapeutically, in people already infected with HIV. It's a complex subject and my intention was to communicate the results as simply and clearly as possible, with the relevance to people with HIV up front. We will absolutely report on the human version when the data are in.
October 14, 2010 • New York, NY